Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Esophagus
Published in: Esophagus 1/2019

01-01-2019 | Review Article

Interactions between Helicobacter pylori and gastroesophageal reflux disease

Author: Oya Yucel

Published in: Esophagus | Issue 1/2019

Login to get access

Abstract

Interactions between Helicobacter Pylori (HP) and gastroesophageal reflux disease (GERD) are a complex issue. Several pathophysiological factors influence the development and the course of GERD, HP infection might be only one of these. Many studies emphasize the co-existence of these diseases. HP infection could contribute to GERD through both a protective and an aggressive role. Gastric acid secretion is a key factor in the pathophysiology of reflux esophagitis. Depending on the type of gastritis related to HP, acid secretion may either increase or decrease. Gastritis in corpus leads to hypoacidity, while antrum gastritis leads to hyperacidity. In cases of antral gastritis and duodenal ulcers which have hyperacidity, the expectation is an improvement in pre-existing reflux esophagitis after eradication of HP. In adults, HP infection is often associated with atrophic gastritis in the corpus. Atrophic gastritis may protect against GERD. Pangastritis which leads to gastric atrophy is commonly associated with CagA strains of HP and it causes more severe gastric inflammation. In case of HP-positive corpus gastritis in the stomach, pangastritis, and atrophic gastritis, reflux esophagitis occurs frequently after eradication of HP. Nonetheless, as a predisposing disease of gastric cancer, HP should be treated. In conclusion, as the determinative factors affecting GERD involving in HP, detailed data on the location of gastric inflammation and CagA positivity should be obtained by the studies at future.
Literature
1.
Ghoshal UC, Chourasia D. Gastroesophageal reflux disease and Helicobacter pylori: what may be the relationship? J Neurogastroenterol Motil. 2010;16:243–50.CrossRefPubMedPubMedCentral
2.
Labenz J, Blum AL. Curing Hp infection in patients with duodenal ulcer may provoke reflux oesophagitis. Gastroenterology. 1997;112:1442–7.CrossRefPubMed
3.
Schwizer W, Fox M. Helicobacter pylori and gastroesophageal reflux disease: a complex organism in a complex host. J Pediatr Gastroenterol Nutr. 2004;38:12–5.CrossRefPubMed
4.
Manes G, Esposito P, Lioniello M, et al. Manometric and pH metric features in gastroesophageal reflux disease patients with and without Helicobacter pylori infection. Dig Liver Dis. 2000;32:372–7.CrossRefPubMed
5.
Koike T, Ohara S, Sekine H, Iijima K, Abe Y, Kato K, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut. 2001;49:330–4.CrossRefPubMedPubMedCentral
6.
7.
Grande M, Cadeddu F, Villa M, Attina GM, Muzi MG, Nigro C, et al. Helicobacter pylori and gastroesophageal reflux disease. World J Surg Oncol. 2008;6:74.CrossRefPubMedPubMedCentral
8.
Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol. 1999;94:3268–72.CrossRef
9.
Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol. 2000;95:914–20.CrossRefPubMed
10.
Wu JCY, Chan FKL, Wong SK, et al. Effect of H pylori eradication on esophageal acid exposure in patients with reflux esophagitis. Aliment Pharmacol Therap. 2002;16:545–52.CrossRef
11.
Sugimoto M, Uotani T, Ichikawa H, Andoh A, Furuta T. Gastroesophageal reflux disease in time covering eradication for all patients infected with Helicobacter pylori in Japan. Digestion. 2016;93:24–31.CrossRefPubMed
12.
Lupu VV, Ignat A, Ciubotariu G, Ciubară A, Moscalu M, Burlea M. Helicobacter pylori infection and gastroesophageal reflux in children. Dis Esophagus. 2016;29:1007–12.CrossRefPubMed
13.
Zentiline P, Iritano E, Vignale C, et al. Helicobacter pylori infection is not involved in the pathogenesis of either erosive or non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;17:1057–64.CrossRef
14.
Sharma P, Vakil N. Helicobacter pylori and reflux disease. Aliment Pharmacol Ther. 2003;17:287–305.CrossRef
15.
Moon A, Solomon A, Beneck D, Cunningham-Rundles S. Positive association between Helicobacter pylori and gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr. 2009;49:283–8.CrossRefPubMedPubMedCentral
16.
Hackelsberger A, Gunther T, Schultze V, et al. Role of aging in the expression of Helicobacter pylori gastritis in the antrum, corpus, and cardia. Scand J Gastroenterol. 1999;34:138–43.CrossRefPubMed
17.
Xinias I, Maris T, Mavroudi A, Panteliadis C, Vandenplas Y. Helicobacter pylori infection has no impact on manometric and pH-metric findings in adolescents and young adults with gastroesophageal reflux and antral gastritis: eradication results to no significant clinical improvement. Pediatr Rep. 2013;5:e3.CrossRefPubMedPubMedCentral
18.
Daugule I, Rowland M. Helicobacter pylori infection in children. Helicobacter. 2008;13(Suppl 1):41–6.CrossRefPubMed
19.
Graham DY, Yamaoka YH. H. Pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter. 1998;3:145–51.CrossRefPubMed
20.
Levine A, Milo T, Broide E, et al. Influence of Helicobacter pylori eradication on gastroesophageal reflux symptoms and epigastric pain in children and adolescents. Pediatrics. 2004;113:54–8.CrossRefPubMed
21.
Lipshutz W, Hughes W, Cohen S. The genesis of lower esophageal sphincter pressure: its identification through the use of gastrin antiserum. J Clin Invest. 1972;51:522–9.CrossRefPubMedPubMedCentral
22.
Goyal RK, McGuigan JE. Is gastrin a major determinant of basal lower esophageal sphincter pressure? A double-blind controlled study using high titer gastrin antiserum. J Clin Invest. 1976;57:291–300.CrossRefPubMedPubMedCentral
23.
Iijima K, Koike T, Shimosegawa T. Reflux esophagitis triggered after Helicobacter pylori eradication: a noteworthy demerit of eradication therapy among the Japanese? Front Microbiol. 2015;6:566.PubMedPubMedCentral
24.
Ishiki K, Mizuno M, Take S, et al. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease. Clin Gastroenterol Hepatol. 2004;2:474–9.CrossRefPubMed
25.
Laine Loren, Sugg Jennifer. Effect of HP eradication on development of GERD symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol. 2002;97:2992–7.CrossRefPubMed
26.
Muramatsu A, Azuma T, Okajima T, et al. Evaluation of treatment for gastrooesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan. Aliment Pharmacol Ther. 2004;20(Suppl 1):102–6.CrossRefPubMed
27.
Vaira D, Vakil N, Rugge M, et al. Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut. 2003;52:1543–7.CrossRefPubMedPubMedCentral
28.
Minatsuki C, Yamamichi N, Shimamoto T, Kakimoto H, Takahashi Y, Fujishiro M, et al. Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. PLoS ONE. 2013;8(7):e69891.CrossRefPubMedPubMedCentral
29.
Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, Wu MS, Lin JT. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676–82.CrossRefPubMed
30.
Tan J, Wang Y, Sun X, Cui W, Ge J, Lin L. The effect of Helicobacter pylori eradication therapy on the development of gastroesophageal reflux disease. Am J Med Sci. 2015;349:364–71.CrossRefPubMed
31.
Wang XT, Zhang M, Chen CY, Lyu B. Helicobacter pylori eradication and gastroesophageal reflux disease: a Meta-analysis. Zhonghua Nei Ke Za Zhi. 2016;55:710–6 (Abstract).PubMed
32.
Hamada H, Haruma K, Mihara M, Kamada T, Yoshihara M, Sumii K, et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther. 2000;14:729–35.CrossRefPubMed
33.
34.
Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol. 2006;4:398–407.CrossRefPubMed
35.
Stadtlander CT, Waterbor JW. Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis. 1999;20:2195–208.CrossRefPubMed
36.
Raghunath AS, Hungin AP, Wooff D, Childs S. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther. 2004;20:733–44.CrossRefPubMed
37.
Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007;5:1413–7.CrossRefPubMed
38.
Wang C, Yuan Y, Hunt RH. Helicobacter pylori infection and Barrett’s esophagus: a systematic review and meta-analysis. Am J Gastroenterol. 2009;104:492–500.CrossRefPubMed
39.
Fischbach LA, Nordenstedt H, Kramer JR, Gandhi S, Dick-Onuoha S, Lewis A, et al. The association between Barrett’s esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter. 2012;17:163–75.CrossRefPubMedPubMedCentral
40.
McColl KE. Review article: Helicobacter pylori and gastro-oesophageal reflux disease—the European perspective. Aliment Pharmacol Ther. 2004;20(Suppl. 8):36–9.CrossRefPubMed
41.
Xie T, Cui X, Zheng H, Chen D, He L, Jiang B. Metaanalysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013;25:1195–205.PubMed
42.
43.
44.
Gold BD. Helicobacter pylori infection in children. Curr Probl Pediatr Adolesc Health Care. 2001;31:247–66.CrossRefPubMed
45.
Shavalipour A, Malekpour H, Dabiri H, Kazemian H, Zojaji H, Bahroudi M. Prevalence of cytotoxin-associated genes of Helicobacter pylori among Iranian GERD patients. Gastroenterol Hepatol Bed Bench. 2017;10:178–83.PubMedPubMedCentral
46.
47.
Park JJ, Kim JW, Kim HJ, et al. The prevalence of and risk factors for Barrett’s esophagus in a Korean population: a nationwide multicenter prospective study. J Clin Gastroenterol. 2009;43:907–14.CrossRefPubMed
48.
Peng S, Cui Y, Xiao YL, et al. Prevalence of erosive esophagitis and Barrett’s esophagus in the adult Chinese population. Endoscopy. 2009;41:1011–7.CrossRefPubMed
49.
Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44:518–34.CrossRef
50.
Miyamoto M, Haruma K, Kuwabara M, Nagano M, Okamoto T, Tanaka M. High incidence of newly-developed gastroesophageal reflux disease in the Japanese community: a 6-year follow-up study. J Gastroenterol Hepatol. 2008;23:393–7.CrossRef
51.
Sharma P, Wani S, Romero Y, Johnson D, Hamilton F. Racial and geographic issues in gastroesophageal reflux disease. Am J Gastroenterol. 2008;103:2669–80.CrossRefPubMed
52.
Boeckxstaens G, El-Serag HB, Smout AJPM, Kahrilas PJ. Republished: symptomatic reflux disease: the present, the past and the future. Postgrad Med J. 2015;91:46–54.CrossRefPubMed
53.
Sherman P, Czinn S, Drumm B, Gottrand F, Kawakami E, Madrazo A, Oderda G, Seo JK, Sullivan P, Toyoda S, Weaver L, Wu TC. Helicobacter pylori infection in children and adolescents: working group report of the first world congress of pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr. 2002;35(Suppl 2):S128–33.CrossRefPubMed
54.
Blecker U. Helicobacter pylori-associated gastroduodenal disease in childhood. South Med J. 1997;90:570–6.CrossRefPubMed
55.
Israel DM, Hassall E. Treatment and long-term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children. J Pediatr. 1993;123:53–8.CrossRefPubMed
56.
Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol. 1993;88:1860–4.PubMed
57.
Hoepler W, Hammer K, Hammer J. Gastric phenotype in children with Helicobacter pylori infection undergoing upper endoscopy. Scand J Gastroenterol. 2011;46:293–8.CrossRefPubMed
58.
Langner C, Schneider NI, Plieschnegger W, Schmack B, Bordel H, Höfler B, Eherer AJ, Wolf EM, Rehak P, Vieth M. Cardiac mucosa at the gastro-oesophageal junction: indicator of gastro-oesophageal reflux disease? Data from a prospective central European multicentre study on histological and endoscopic diagnosis of oesophagitis (histoGERD trial). Histopathology. 2014;65:81–9.CrossRefPubMed
59.
Guiraldes E, Peña A, Duarte I, Triviño X, Schultz M, Larraín F, Espinosa MN, Harris P. Nature and extent of gastric lesions in symptomatic Chilean children with Helicobacter pylori associated gastritis. Acta Paediatr. 2002;91:39–44.CrossRefPubMed
60.
Carvalho MA, Machado NC, Ortolan EV, Rodrigues MA. Upper gastrointestinal histopathological findings in children and adolescents with nonulcer dyspepsia with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr. 2012;55:523–9.CrossRefPubMed
61.
Kato S, Nishino Y, Ozawa K, Konno M, Maisawa S, Toyoda S, Tajiri H, Ida S, Fujisawa T, Iinuma K. The prevalence of Helicobacter pylori in Japanese children with gastritis or peptic ulcer disease. J Gastroenterol. 2004;39:734–8.CrossRefPubMed
62.
Macarthur C, Saunders N, Feldman W. Helicobacter pylori, gastroduodenal disease, and recurrent abdominal pain in children. JAMA. 1995;273:729–34.CrossRefPubMed
63.
Bedoya A, Garay J, Sanzón F, Bravo LE, Bravo JC, Correa H, Craver R, Fontham E, Du JX, Correa P. Histopathology of gastritis in Helicobacter pylori-infected children from populations at high and low gastric cancer risk. Hum Pathol. 2003;34:206–13.CrossRefPubMed
64.
Mungan Z, Pınarbaşı Şimşek B. Gastroesophageal reflux disease and the relationship with Helicobacter pylori. Turk J Gastroenterol. 2017;28(Suppl 1):S61–7.CrossRefPubMed
65.
Pollet S, Gottrand F, Vincent P, et al. Gastroesophageal reflux disease and Helicobacter pylori infection in neurologically impaired children: inter-relations and therapeutic implications. J Pediatr Gastroenterol Nutr. 2004;38:70–4.CrossRefPubMed
66.
Kalach N, Bontems P, Koletzko S, Mourad-Baars P, Shcherbakov P, Celinska-Cedro D, Iwanczak B, Gottrand F, Martinez-Gomez MJ, Pehlivanoglu E, Oderda G, Urruzuno P, Casswall T, Lamireau T, Sykora J, Roma-Giannikou E, Veres G, Wewer V, Chong S, Charkaluk ML, Mégraud F, Cadranel S. Frequency and risk factors of gastric and duodenal ulcers or erosions in children: a prospective 1-month European multicenter study. Eur J Gastroenterol Hepatol. 2010;22:1174–81.CrossRefPubMed
67.
Oderda G, Shcherbakov P, Bontems P, Urruzuno P, Romano C, Gottrand F, Gómez MJ, Ravelli A, Gandullia P, Roma E, Cadranel S, De Giacomo C, Canani RB, Rutigliano V, Pehlivanoglu E, Kalach N, Roggero P, Celinska-Cedro D, Drumm B, Casswall T, Ashorn M, Arvanitakis SN. Results from the pediatric European register for treatment of Helicobacter pylori (PERTH). Helicobacter. 2007;12:150–6.CrossRefPubMed
68.
Tam YH, Lee KH, To KF, Chan KW, Cheung ST. Helicobacter pylori-positive versus Helicobacter pylori-negative idiopathic peptic ulcers in children with their long-term outcomes. J Pediatr Gastroenterol Nutr. 2009;48:299–305.CrossRefPubMed
69.
Daugule I, Rumba I, Engstrand L, Ejderhamn J. Infection with cagA-Positive and cagA-Negative types of Helicobacter pylori among children and adolescents with gastrointestinal symptoms in Latvia. Eur J Clin Microbiol Infect Dis. 2003;22:622–4.PubMed
70.
Arents NL, Thijs JC, van Zwet AA, Kleibeuker JH. Does the declining prevalence of Helicobacter pylori unmask patients with idiopathic peptic ulcer disease? Trends over an 8 year period. Eur J Gastroenterol Hepatol. 2004;16:779–83.CrossRefPubMed
71.
Kato S, Kikuchi S, Nakajima S. When does gastric atrophy develop in Japanese children? Helicobacter. 2008;13:278–81.CrossRef
72.
Kekki M, Samloff IM, Varis K, Ihamäki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol Suppl. 1991;186:109–16.CrossRefPubMed
73.
Waldum HL, Sagatun L, Mjønes P. Gastrin and gastric cancer. Front Endocrinol (Lausanne). 2017;8:1.CrossRef
74.
75.
Whitney AE, Guarner J, Hutwagner L, Gold BD. Helicobacter pylori gastritis in children and adults: comparative histopathologic study. Ann Diagn Pathol. 2000;4:279–85.CrossRefPubMed
76.
Usta Y, Saltk-Temizel IN, Ozen H. Gastric atrophy and intestinal metaplasia in Helicobacter pylori infection. J Pediatr Gastroenterol Nutr. 2004;38:548.CrossRefPubMed
77.
Oztürk Y, Büyükgebiz B, Arslan N, Ozer E. Antral glandular atrophy and intestinal metaplasia in children with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr. 2003;37:96–7.CrossRefPubMed
78.
Guarner J, Bartlett J, Whistler T, Pierce-Smith D, Owens M, Kreh R, Czinn S, Gold BD. Can pre-neoplastic lesions be detected in gastric biopsies of children with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr. 2003;37:309–14.CrossRefPubMed
79.
Boukthir S, Mrad SM, Kalach N, Sammoud A. Gastric atrophy and Helicobacter pylori infection in children. Trop Gastroenterol. 2009;30:107–9.PubMed
80.
Pacifico L, Anania C, Osborn JF, Ferraro F, Chiesa C. Consequences of Helicobacter pylori infection in children. World J Gastroenterol. 2010;16:5181–94.CrossRefPubMedPubMedCentral
81.
Matsuhisa T, Aftab H. Observation of gastric mucosa in Bangladesh, the country with the lowest incidence of gastric cancer, and Japan, the country with the highest incidence. Helicobacter. 2012;17:396–401.CrossRefPubMedPubMedCentral
82.
Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, et al. Helicobacter pylori Infection and the Risk of Barrett’s Oesophagus: a Community-Based Study. Gut. 2008;57:727–33.CrossRefPubMed
83.
Inomata Y, Koike T, Ohara S, Abe Y, Sekine H, Iijima K, et al. Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status. Am J Gastroenterol. 2006;101:926–33.CrossRefPubMed
84.
Ricuarte O, Gutierrez O, Cardona H, Kim JG, Graham DY, El-Zimaity HM. Atrophic gastritis in young children and adolescents. J Clin Pathol. 2005;58:1189–93.CrossRefPubMedPubMedCentral
85.
Riddell RH. Pathobiology of Helicobacter pylori infection in children. Can J Gastroenterol. 1999;13:599–603.CrossRefPubMed
86.
Ghoshal UC, Tiwari S, Dhingra S, et al. Frequency of Helicobacter pylori and CagA antibody in patients with gastric neoplasms and controls: the Indian enigma. Dig Dis Sci. 2008;53:1215–22.CrossRefPubMed
87.
Sayehmiri F, Kiani F, Sayehmiri K, Soroush S, Asadollahi K, Alikhani MY, Delpisheh A, Emaneini M, Bogdanović L, Varzi AM, Zarrilli R, Taherikalani M. Prevalence of cagA and vacA among Helicobacter pylori-infected patients in Iran: a systematic review and meta-analysis. J Infect Dev Ctries. 2015;9:686–96.CrossRefPubMed
88.
Nawfal RH, Mohammadi M, Talebkhan Y, Doraghi MP, Letley DK, Muhammad M, Argent HR, Atherton CJ. Differences in virulence markers between Helicobacter pylori strains from Iraq and those from Iran: potential importance of regional differences in H. pylori- associated disease. J Clin Microbiol. 2008;46:1774–9.CrossRef
89.
Saribasak H, Salih BA, Yamaoka Y, Sander E. Analysis of Helicobacter pylori genotypes and correlation with clinical outcome in Turkey. J Clin Microbiol. 2004;42:1648–51.CrossRefPubMedPubMedCentral
90.
Chiba H, Gunji T, Sato H, Iijima K, Fujibayashi K, Okumura M, et al. A cross-sectional study on the risk factors for erosive esophagitis in young adults. Intern Med. 2012;51:1293–9.CrossRefPubMed
91.
Azuma T, Yamazaki S, Yamakawa A, Ohtani M, Muramatsu A, Suto H, et al. Association between diversity in the Src homology 2 domain—containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer. J Infect Dis. 2004;189:820–7.CrossRefPubMed
92.
Luzza F, Pensabene L, Imeneo M, Mancuso M, Giancotti L, La Vecchia AM, Costa MC, Strisciuglio P, Pallone F. Antral nodularity and positive CagA serology are distinct and relevant markers of severe gastric inflammation in children with Helicobacterpylori infection. Helicobacter. 2002;7(1):46–52.CrossRefPubMed
93.
Vorobjova T, Grünberg H, Oona M, Maaroos HI, Nilsson I, Wadström T, Covacci A, Uibo R. Seropositivity to Helicobacter pylori and CagA protein in schoolchildren of different ages living in urban and rural areas in southern Estonia. Eur J Gastroenterol Hepatol. 2000;12:97–101.CrossRefPubMed
94.
Sokucu S, Ozden AT, Suoglu OD, Elkabes B, Demir F, Cevikbas U, et al. CagA positivity and its association with gastroduodenal disease in Turkish children undergoing endoscopic investigation. J Gastroenterol. 2006;41:533–9.CrossRefPubMed
95.
Mourad-Baars P, Hussey S, Jones NL. Helicobacter pylori infection and childhood. Helicobacter. 2010;15:53–9.CrossRefPubMed
96.
Kütükçüler N, Aydogdu S, Göksen D, Caglayan S, Yagcyi RV. Increased mucosal inflammatory cytokines in children with Helicobacter pylori-associated gastritis. Acta Paediatr. 1997;86:928–31.CrossRefPubMed
97.
Bytzer P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. European helicobacter study group. Management of Helicobacter pylori infection–the Maastricht IV/Florence consensus report. Gut. 2012;61:646–64.CrossRef
98.
Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1–20.CrossRefPubMed
99.
Kawanishi M. Development of reflux esophagitis following Helicobacter pylori eradication. J Gastroenterol. 2005;40:1024–8.
100.
Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida To, Yokota K, et al. Helicobacter pylori eradication may induce de novo, but transient and mild, reflux esophagitis: prospective endoscopic evaluation. J Gastroenterol Hepatol. 2009;24:107–13.
101.
Inoue H, Imoto I, Taguchi Y, Kuroda M, Nakamura M, Horiki N, et al. Reflux esophagitis after eradication of Helicobacter pylori is associated with the degree of hiatal hernia. Scand J Gastroenterol. 2004;39:1061–5.
102.
Nam SY, Choi IJ, Ryu KH, Kim BC, Kim CG, Nam BH. Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. Am J Gastroenterol. 2010;105:2153–62.
103.
Kim N, Lim SH, Lee KH. No protective role of Helicobacter pylori in the pathogenesis of reflux esophagitis in patients with duodenal or benign gastric ulcer in Korea. Dig Dis Sci. 2001;46:2724–32.
104.
Kim N, Lee SW, Kim JI, Baik GH, Kim SJ, Seo GS, et al. Effect of Helicobacter pylori eradication on the development of reflux esophagitis and gastroesophageal reflux symptoms: a nationwide multi-center prospective study. Gut Liver. 2011;5:437–46.
105.
Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R, et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut. 2004;53:174–9.
106.
Vakil N, Talley NJ, Stolte M, Sundin M, Junghard O, Bolling-Sternevald O. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 2006;24:55–63.
107.
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646–64.
108.
Bytzer P, Aalykke C, Rune S, Weywadt L, Gjorup T, Eriksen J, et al. Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group. Scand J Gastroenterol. 2000;35:1023–32.
109.
Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project. BMJ. 2004;328:1417.
110.
Ott EA, Mazzoleni LE, Edelweiss MI, Sander GB, Wortmann AC, Theil AL, et al. Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:1231–9.
111.
Befrits R, Sjostedt S, Odman B, Sorngard H, Lindberg G. Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter. 2000;5:202–5.
112.
Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology. 2001;121:1120–6.
113.
Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2012;47:129–35.
114.
Cremonini F, Di Caro S, Delgado-Aros S, Sepulveda A, Gasbarrini G, Gasbarrini A, Camilleri M. Meta analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;18:279–89.
115.
Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol. 2010;105:1007–13.
Metadata
Title
Interactions between Helicobacter pylori and gastroesophageal reflux disease
Author
Oya Yucel
Publication date
01-01-2019
Publisher
Springer Singapore
Published in
Esophagus / Issue 1/2019
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-018-0637-5

Other articles of this Issue 1/2019

Esophagus 1/2019 Go to the issue

Original Article

A new esophageal elongation technique for long-gap esophageal atresia: in vitro comparison of myotomy techniques

Original Article

Survival benefit of multimodal local therapy for repeat recurrence of thoracic esophageal squamous cell carcinoma after esophagectomy

Special Article

Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1

Special Article

Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2

Original Article

Perioperative enteral supplementation with glutamine, fiber, and oligosaccharide reduces early postoperative surgical stress following esophagectomy for esophageal cancer

Original Article

Circumferential distribution and clinical characteristics of esophageal cancer in lower esophagus: differences related to histological subtype
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits